trending Market Intelligence /marketintelligence/en/news-insights/trending/nNWbhTBAbryNSRFIiwgghQ2 content esgSubNav
In This List

Abeona Therapeutics initiates strategic review

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Abeona Therapeutics initiates strategic review

Abeona Therapeutics Inc. said it has initiated a strategic review, including a sale or merger of the company, in order to advance its business and maximize shareholder value.

The company retained Jefferies LLC as its financial adviser to help with the evaluation of its strategic options, which might also entail the partnering of its various clinical and preclinical programs.

The biopharmaceutical company's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, an inherited disease affecting the skin and other organs.

Abeona's clinical programs also include ABO-102 and ABO-101, AAV9-based gene therapies for types A and B of Sanfilippo syndrome, a rare autosomal recessive lysosomal storage disease.